Co-Authors
This is a "connection" page, showing publications co-authored by BING Z CARTER and NAVEEN PEMMARAJU.
Connection Strength
0.812
-
Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells. Blood. 2023 09 21; 142(12):1056-1070.
Score: 0.230
-
Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv. 2021 08 24; 5(16):3163-3173.
Score: 0.199
-
SMAC mimetics as potential cancer therapeutics in myeloid malignancies. Br J Haematol. 2019 04; 185(2):219-231.
Score: 0.168
-
Glioblastoma and acute myeloid leukemia: malignancies with striking similarities. J Neurooncol. 2018 Jan; 136(2):223-231.
Score: 0.154
-
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia. Cancer. 2024 Aug 01; 130(15):2652-2659.
Score: 0.060